Please try another search
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Name | Age | Since | Title |
---|---|---|---|
Kapil Dhingra | 65 | 2021 | Non-Executive Chairman |
Karen J. Wilson | 61 | 2021 | Independent Non-Executive Director |
Stephen Allen Hurly | 56 | 2019 | CEO, President & Executive Director |
James Julian Noble | 65 | 2022 | Independent Non-Executive Director |
Andrea van Elsas | 58 | 2018 | Chairman of Advisory Board |
Padmanee Sharma | - | 2020 | Member of Advisory Board |
James Patrick Allison | - | 2020 | Member of Advisory Board |
K. Dane Wittrup | - | - | Member of Advisory Board |
Madhav V. Dhodapkar | - | - | Member of Advisory Board |
Jay Thomas Backstrom | 69 | 2022 | Non-Executive Director |
Dieter Kabelitz | - | - | Member of Advisory Board |
Mary E. Wadlinger | 64 | 2023 | Non-Executive Director |
Christy J. Oliger | 54 | 2023 | Non-Executive Director |
Peter A. Kiener | 72 | 2023 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review